KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 2

Changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and correlation with curative effect

Zibin TIAN
Chunhua BI
Deyu HUANG
Jing JIANG
Yueping JIANG
Cheng BIAN
Hui WANG
Sayfa
286–292
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

At 48 weeks after entecavir treatment, sPD-1 amounts in the HBeAgseroconversion group were significantly higher than the values of the HBeAg-negative and HBeAg-positive groups. sPD-1 levels inpatients with alanine aminotransferase (ALT) returning to normal were significantly higher than in those with ALT not returning tonormal. sPD-1 levels in treated patients with no HBV-DNA were significantly higher than in those with HBV-DNA remaining positive.sPD-1 was negatively correlated with ALT and HBV-DNA at 12, 24, and 48 weeks after entecavir treatment.Conclusion: sPD-1 may play a certain role in chronic hepatitis B and has a close relationship with the curative effect of entecavir.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: This study aimed to assess expression changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patientswith entecavir treatment and explore the correlation with the curative effect.Materials and methods: A total of 220 HBeAg-positive CHB patients and 207 healthy individuals were included. sPD-1 levels andvirological and biochemical responses were assessed at baseline and at 12, 24, and 48 weeks in CHB patients after antiviral therapy.Results: sPD-1 levels in HBeAg-positive CHB patients before treatment were significantly lower than those of healthy controls.
📊
Temel Bulgular & Veri:Afterentecavir treatment, sPD-1 levels increased gradually over time.
💡
Sonuç & Katkı:At 48 weeks after entecavir treatment, sPD-1 amounts in the HBeAgseroconversion group were significantly higher than the values of the HBeAg-negative and HBeAg-positive groups. sPD-1 levels inpatients with alanine aminotransferase (ALT) returning to normal were significantly higher than in those with ALT not returning tonormal. sPD-1 levels in treated patients with no HBV-DNA were significantly higher than in those with HBV-DNA remaining positive.sPD-1 was negatively correlated with ALT and HBV-DNA at 12, 24, and 48 weeks after entecavir treatment.Conclusion: sPD-1 may play a certain role in chronic hepatitis B and has a close relationship with the curative effect of entecavir.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: This study aimed to assess expression changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patientswith entecavir treatment and explore the correlation with the curative effect.Materials and methods: A total of 220 HBeAg-positive CHB patients and 207 healthy individuals were included. sPD-1 levels andvirological and biochemical responses were assessed at baseline and at 12, 24, and 48 weeks in CHB patients after antiviral therapy.Results: sPD-1 levels in HBeAg-positive CHB patients before treatment were significantly lower than those of healthy controls. Afterentecavir treatment, sPD-1 levels increased gradually over time. At 48 weeks after entecavir treatment, sPD-1 amounts in the HBeAgseroconversion group were significantly higher than the values of the HBeAg-negative and HBeAg-positive groups. sPD-1 levels inpatients with alanine aminotransferase (ALT) returning to normal were significantly higher than in those with ALT not returning tonormal. sPD-1 levels in treated patients with no HBV-DNA were significantly higher than in those with HBV-DNA remaining positive.sPD-1 was negatively correlated with ALT and HBV-DNA at 12, 24, and 48 weeks after entecavir treatment.Conclusion: sPD-1 may play a certain role in chronic hepatitis B and has a close relationship with the curative effect of entecavir.

🔖

Bu Makaleye Atıf Yap

TIAN, Z., BI, C., HUANG, D., JIANG, J., JIANG, Y., BIAN, C., WANG, H. (2022). Changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and correlation with curative effect. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 2, 286–292. https://ajindex.com/articles/610306

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Stenejohansen K, Barlinn R. Diagnosis of chronic hepatitis B infection. Tidsskr Norske Laege 2013; 133: 1717-1721.
  2. Liaw Y, Chu C. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
  3. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
  4. Webster GJ, Reignat S, Brown DA, Ogg GS, Jones L, Seneviratne SL, Williams R, Dusheiko G, Bertoletti A. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719.
  5. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini E, Andreone P, Missale G. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138: 682-693.
  6. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
  7. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206-210.
  8. Nielsen C, Ohmlaursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cellular Immunol 2005; 235: 109-116.
  9. Xiao H, Huang B, Yuan Y, Li D, Han L, Liu Y, Gong W, Wu F, Zhang G, Feng Z. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007; 13: 1823-1830.
  10. Wu H, Miao M, Zhang G, Hu Y, Ming Z, Zhang X. Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. Immunol Invest 2009; 38: 408-421.
  11. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Chinese J Hepatol 2015; 23: 888-905.
  12. Hao AH, Bian C, Xu YH, Liu HY, Wang T, Huang DY. Correlation of T-lymphocyte subsets with serum HBV-DNA loads and HBeAg title among different clinical types of hepatitis B patients. Prog Mod Biomedicine 2012; 23: 4424-4428.
  13. Wherry EJ, Ha S, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of